The picture is further complicated by the possible ILD-promoting effect of several drugs used to treat RA such as DMARDs (e.g., methotrexate and leflunomide) [25, 26] and biological agents (e.g., anti-TNF alpha and rituximab) [27, 28]. This evidence concerns the gene TNF and interstitial lung disease.